Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Vistusertib in Relapsed/Refractory B-cell Malignancies
NCT03205046Phase 2Terminated
- Sponsor
- Acerta Pharma
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib and vistusertib in diffuse large B-cell lymphoma (DLBCL) and Richter syndrome (RS) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Jun 2017; status: terminated.
02
Drugs
acalabrutinibvistusertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT03205046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205046.